{"id":"W4283011798","doi":"10.1038/s41591-022-01866-4","title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Neurogenetic and Muscular Disorders Research","field":"Medicine","cited_by":295,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; Montreal Children's Hospital","funders":"UCB Pharma; Chugai Pharmaceutical; Genentech; Grifols; Novartis Institutes for BioMedical Research; New South Wales Government; University of Sydney; Sarepta Therapeutics; Cytokinetics; PTC Therapeutics; Children's Hospital of Philadelphia; Children's Medical Research; University of New South Wales; Alexion Pharmaceuticals; AveXis; Biogen","keywords":"Spinal muscular atrophy; SMN1; Medicine; SMA*; Pediatrics; Cohort; Clinical trial; Adverse effect; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009250913,0.0002536565,0.0006857286,0.0001739768,0.0003880699,0.000005388347,0.0002971754,0.0001026736,0.0003247473],"category_scores_gemma":[0.0007709661,0.0001433444,0.0002250553,0.0004673902,0.0003467719,0.00002070555,0.0001312586,0.0006157403,0.000001499928],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008863723,"about_ca_system_score_gemma":0.0003081663,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007475816,"about_ca_topic_score_gemma":0.00005140402,"domain_scores_codex":[0.997398,0.0001521809,0.0004557219,0.0004151922,0.001164415,0.0004145398],"domain_scores_gemma":[0.9981989,0.0003718731,0.0002679208,0.000646778,0.0003517771,0.0001627285],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8549208,0.002377409,0.002584077,0.001774846,0.002893044,0.0001284077,0.001636902,0.0002805862,0.06676212,0.001067901,0.03311032,0.0324636],"study_design_scores_gemma":[0.6130704,0.07514019,0.002198976,0.0003555998,0.003280449,0.000238634,0.0008505842,0.002659193,0.01886135,0.0004277013,0.2824801,0.0004368002],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9775865,0.01206182,0.0007873059,0.002165294,0.0005152943,0.006577666,0.0001176966,0.00003030372,0.0001581275],"genre_scores_gemma":[0.9958314,0.0002381346,0.0007130157,0.0008036745,0.0006588585,0.0008347171,0.0002225771,0.00005883997,0.0006388359],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2493698,"threshold_uncertainty_score":0.5845416,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02059131339486083,"score_gpt":0.3716390112580729,"score_spread":0.3510476978632121,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}